UK healthcare AI commission recommendations (2026)
AI-generated text. This page was generated using artificial intelligence.
National Commission into the Regulation of AI in Healthcare — recommendations[1]
United Kingdom[1]
Advisory recommendations for regulatory reform[1]
Commission report, published September 10, 2026[1]
Government accepted all 44 recommendations in its October 6, 2026 response and set initial delivery priorities; legislation and detailed guidance remain to be developed.[2]
Publication: September 10, 2026. The report does not itself enact its recommendations.[1]
October 6, 2026[2]
The National Commission into the Regulation of AI in Healthcare recommends a framework for oversight across the lifecycle of healthcare AI, with responsibilities extending beyond medical-device regulation. Its September 10, 2026 report advises government; it is not itself a new statute or binding regulatory instrument. The government accepted all 44 recommendations on October 6, 2026 and set initial priorities for implementation.[1][2]
Scope
The report addresses software and AI-enabled medical devices, alongside accountability, transparency, professional practice and organisational governance. It distinguishes medical-device regulation from other applicable frameworks, including data protection and professional standards; not every healthcare AI application is regulated as a medical device.[1]
Recommended changes
The commission calls for proportionate oversight throughout development, deployment, updating and monitoring, with real-world evidence supporting ongoing assurance. It proposes clearer responsibilities for developers, manufacturers, healthcare organisations and professionals, better communication of safety concerns, and stronger patient and public involvement.[1]
Recommendation 14 proposes staged authorisations for suitable devices. Initial deployment would have a controlled scope, safety evidence, risk controls and reporting conditions. Authorisation could expand after specified evidence thresholds are met. The report calls for transparent pathways tailored to technical maturity, clinical needs and patient safety; it does not grant individual products authorisation.[1]
Implementation status
On October 6, 2026, the government accepted all 44 recommendations and committed to a lifecycle-based approach to AI-enabled medical-device oversight. The MHRA said it would issue draft guidance by December 2026 on managing changes to AI devices, consult in 2027 on device qualification and classification, and publish a full implementation roadmap by spring 2027. These are commitments to develop policy and guidance; the response itself does not amend the medical-device regulations.[2][3]
The MHRA opened phase 3 applications for its AI Airlock regulatory sandbox, concentrating on post-market surveillance. Applications remain open on a rolling basis, with October 31 as the cutoff for the current review wave.[4]
Related coverage
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 National Commission into the Regulation of AI in Healthcare, Recommendations for a future regulatory framework, September 10, 2026; executive summary, introduction and recommendation 14.
- ↑ 2.0 2.1 2.2 2.3 UK Government, full response, October 6, 2026.
- ↑ MHRA, October 6, 2026 press release.
- ↑ MHRA, October 6, 2026 application guidance.